- Home
- BAH vs PODD Comparison
BAH vs PODD Comparison
Compare BAH & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | PODD |
|---|---|---|
| Founded | 1914 | 2000 |
| Country | United States | United States |
| Employees | 31500 | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.3B |
| IPO Year | 2010 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BAH | PODD |
|---|---|---|
| Price | $72.53 | $163.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $97.00 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.63 | 1.30 |
| Revenue | ★ $11,217,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | $2.14 | $19.18 |
| P/E Ratio | ★ $9.55 | $121.83 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $59.50 | $138.79 |
| 52 Week High | $114.48 | $354.88 |
Technical Indicators
Market Signals| Indicator | BAH | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 55.69 |
| Support Level | $68.84 | $141.67 |
| Resistance Level | $82.42 | $168.84 |
| Average True Range (ATR) | 2.56 | 5.46 |
| MACD | 1.31 | 0.06 |
| Stochastic Oscillator | 82.37 | 65.67 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.